Natural Product (NP) Details

General Information of the NP (ID: NP9072)
Name
Doxercalciferol
Synonyms
Doxercalciferol; 54573-75-0; Hectorol; 1alpha-Hydroxyergocalciferol; 1-Hydroxyergocalciferol; 1alpha-hydroxyvitamin D2; 1-alpha-Hydroxyvitamin D2; TSA 840; 1-Hydroxyvitamin D2; UNII-3DIZ9LF5Y9; 1alpha-OH-D2; 3DIZ9LF5Y9; 1-alpha-hydroxyergocalciferol; CHEBI:4712; (1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol; MFCD00871065; 1alpha-hydroxyvitamin D2 / 1alpha-hydroxyergocalciferol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3-diol; Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol; 1alpha-OHD2; BRN 4716774; Doxercalciferol [USAN:INN]; Vitamin D2, 1alpha-Hydroxy-; Doxercalciferolum; NCGC00182058-03; 1alphaOHD2; PubChem18823; 1alpha-hydroxy vitamin D2; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-alpha-hydroxy-vitamin D2; DSSTox_CID_14214; DSSTox_RID_79125; Doxercalciferol (USAN/INN); DSSTox_GSID_34214; (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol; SCHEMBL322422; GTPL2790; CHEMBL1200810; DTXSID1034214; TSA-840; ACT06836; EX-A4428; ZINC4641374; Tox21_112978; HSCI1_000341; LMST03010028; AKOS005146517; CS-0395; DB06410; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1-alpha,3-beta,5Z,7E,22E)-; BS-17040; GZ427397; HY-32348; CAS-54573-75-0; V1826; C08211; D01009; W-5181; 42163-EP2298768A1; 42163-EP2311808A1; 42163-EP2311829A1; 573D750; Q5303688; Doxercalciferol, >=98% (HPLC), solubility: >10 mg/mL in DMSO; Doxercalciferol, United States Pharmacopeia (USP) Reference Standard; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1alpha,3beta,5Z,7E,22E)-; (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7?-methyl-1-[(1R,2E)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; (1R,3S,5Z)-4-Methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-7alpha-methyl-1-[(1R,2E)-1,4,5-trimethyl-2-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Chronic kidney disease [ICD-11: GB61] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.163
 
MDCK Permeability
 -4.854
 
PAMPA
 - -
 
HIA
 - - -
 
Distribution
VDss
 -0.085
 
PPB
 99.1%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - -
CYP3A4 substrate
 ++
CYP2B6 inhibitor
 +++
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 +
 
Excretion
CLplasma
 8.301
 
T1/2
 0.781
Toxicity
DILI
 ++
 
Rat Oral Acute Toxicity
 +++
 
FDAMDD
 +++
 
Respiratory
 +++
 
Human Hepatotoxicity
 ++
 
Ototoxicity
 ++
 
Drug-induced Nephrotoxicity
 +++
 
Drug-induced Neurotoxicity
 -
 
Hematotoxicity
 ++
 
Genotoxicity
 ++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C28H44O2
PubChem CID
5281107
Canonical SMILES
CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
InChI
1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
InChIKey
HKXBNHCUPKIYDM-CGMHZMFXSA-N
CAS Number
CAS 54573-75-0
ChEBI ID
CHEBI:4712
TTD Drug ID
D0G5CF
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          KML001      Lung cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 A combination of KML001 with doxercalciferol showed a synergistic effect on ALL cell lines.
Target and Pathway
Target(s) Vitamin D3 receptor (VDR)  Molecule Info  [3]
KEGG Pathway Endocrine and other factor-regulated calcium reabsorption Click to Show/Hide
2 Mineral absorption
3 Tuberculosis
NetPath Pathway IL4 Signaling Pathway Click to Show/Hide
Panther Pathway Vitamin D metabolism and pathway Click to Show/Hide
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling Click to Show/Hide
2 Direct p53 effectors
3 RXR and RAR heterodimerization with other nuclear receptor
4 Retinoic acid receptors-mediated signaling
5 Validated transcriptional targets of deltaNp63 isoforms
6 Validated transcriptional targets of TAp63 isoforms
Reactome Nuclear Receptor transcription pathway Click to Show/Hide
WikiPathways Ovarian Infertility Genes Click to Show/Hide
2 Nuclear Receptors in Lipid Metabolism and Toxicity
3 Nuclear Receptors Meta-Pathway
4 Vitamin D Receptor Pathway
5 Drug Induction of Bile Acid Pathway
6 Nuclear Receptors
7 Vitamin D Metabolism
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2790).
Reference 2 KML001 and doxercalciferol induce synergistic antileukemic effect in acute lymphoid leukemia cells. Oncol Rep. 2017 Jul;38(1):481-487.
Reference 3 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
 Download Picture         KEGG Link